Andrea Alejo, MD
Internal Medicine · Gloucester, VANPI 1043645872
Payments from drug & device makers
Across 149 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$348
- Lilly USA, LLC$288
- AbbVie$216
- AstraZeneca$185
- Pfizer$148
- Abbott$133
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,643100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $348 |
| Lilly USA, LLC | 17 | $288 |
| AbbVie(2 entities) | 11 | $216 |
| AstraZeneca | 12 | $185 |
| Pfizer | 9 | $148 |
| Abbott | 7 | $133 |
| GSK | 7 | $117 |
| Amgen | 6 | $115 |
| E.r. Squibb & Sons, L.L.C. | 7 | $106 |
| Mannkind Corporation | 4 | $96 |
| Harmony Biosciences LLC | 3 | $72 |
| Johnson & Johnson | 5 | $70 |
| Amarin Pharma, Inc. | 5 | $67 |
| Exact Sciences | 3 | $57 |
| Xeris Pharmaceuticals, Inc. | 3 | $53 |
| Shield Therapeutics Inc | 2 | $48 |
| Boehringer Ingelheim | 2 | $47 |
| Merck | 3 | $46 |
| Inspire Medical Systems, Inc. | 1 | $40 |
| Biohaven Pharmaceuticals, Inc. | 2 | $37 |
| Viatris Specialty LLC | 2 | $37 |
| Ascendis Pharma Endocrinology Inc | 2 | $36 |
| Mylan Specialty L.p. | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Dexcom, Inc. | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 2 | $33 |
| BETA Bionics, Inc. | 1 | $32 |
| Grifols USA, LLC | 1 | $28 |
| Averitas Pharma Inc. | 1 | $20 |
| Pulmonx Corporation | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
How this compares
$2,643 in reported general payments places this provider in the 85th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 119 | $112,871 |
| JanuviaSitagliptin Phosphate | 65 | $76,210 |
| OzempicSemaglutide | 48 | $69,569 |
| XareltoRivaroxaban | 60 | $63,709 |
| TrulicityDulaglutide | 26 | $43,306 |
| MounjaroTirzepatide | 25 | $39,729 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $28,396 |
| ProliaDenosumab | 16 | $27,623 |
| FarxigaDapagliflozin Propanediol | 31 | $25,119 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 129 | $22,490 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $22,278 |
| JardianceEmpagliflozin | 13 | $19,433 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $13,847 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 32 | $8,084 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,616 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $148 | $112,871119 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $288 | $84,50064 claims |
| MerckJanuvia | $46 | $76,21065 claims |
| Novo NordiskOzempic | $348 | $69,56948 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $117 | $68,305109 claims |
| Johnson & JohnsonXarelto | $70 | $63,70960 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $185 | $35,22254 claims |
| AmgenProlia | $115 | $27,62316 claims |
| Boehringer IngelheimJardiance | $47 | $19,43313 claims |
| AbbVieSynthroid | $216 | $2,84281 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Gloucester
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
- Richard JacksonRichmond$2.5M
- Sue BrownCharlottesville$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.